3月24日周一，港股上市公司德琪医药-B（06996）股价盘中大涨22%，引起市场广泛关注。截至发稿时，该股报4.14港元，涨幅收窄至18.57%，成交额达1501.48万港元。
此轮涨势主要受公司最新发布的年度业绩报告推动。德琪医药-B于3月21日公布截至2024年12月31日止的年度业绩，显示公司各项财务指标均有显著改善。报告期内，公司实现收入人民币9195万元，同比增长36.62%；研发开支降至2.59亿元，同比减少36.18%；年内亏损收窄至3.19亿元，同比减少45.07%；经调整年内亏损为3.05亿元，同比减少42.95%。
值得注意的是，尽管公司核心产品希维奥®（塞利尼索）在2023年12月纳入国家医保目录后价格大幅下调，但其销售表现依然强劲。公司表示，收入增长主要得益于中国内地市场的加速贡献，该地区收入增长27.4%，主要由销量大幅上升所驱动。这一业绩表现显示了公司产品的市场竞争力和未来增长潜力，从而提振了投资者信心，推动股价大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.